Back to results
TerminatedPhase 1

Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects

NCT00470925

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States

View on ClinicalTrials.gov
Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects — TrialFind